Transparency Market Research

Transparency Market
Research
Peptide Therapeutics Market is
growing at a CAGR of 8.7% from
2!" to 2!#. $% Transparenc%
Market Research.
Single User License:
USD 4595
Multi User License:
USD 7595
Corporate User License:
USD 10595
Peptide Therapeutics Market is &'pected to Reach ()* 2+.,
$i--ion G-o.a--% in 2!8/ Transparenc% Market Research
Transparency Market Research
)tate Tower0
#0 )tate )treet0 )uite 7.
A-.an%0 12 !227
(nited )tates
www.transparenc%marketresearch.com
sa-es3transparenc%marketresearch.com
128 Page Report
Pulis!e" Date
1#$Marc!$201#
%u& 'o(
Re)uest Sa*ple
Press Release
Peptide Therapeutics
Market
Peptide Therapeutics Market was valued at USD 14.1 billion in 2013 and is estiated to reach a
arket worth USD 2!.4 billion in 201" at a #$%& o' (.)* 'ro 2013 to 201".
%ro(se t!e +ull report at !ttp:,,(((-transparenc&*ar.etresearc!-co*,pepti"e$
t!erapeutics$*ar.et-!t*l
The +rowth o' the arket is driven b, 'actors such as risin+ incidences o' cardiovascular
diseases- etabolic diseases and technolo+ical enhanceent in peptide s,nthesis. The $sian
re+ion o.ers 'uture +rowth prospects to the peptide industr, owin+ to vast unet edical needs
and risin+ disposable incoe o' patients.
$on+st the application arket- the cancer peptide se+ent accounted 'or the lar+est share o'
appro/iatel, 21* and is e/pected to +row at a health, #$%& durin+ the 'orecast period. The
neuropeptides application se+ent is anticipated to +row at a #$%& o' ".4* 'ro 2012 to 201(
due to the rise in nuber o' neurolo+ical disorders such as $l0heier1s and Parkinson1s disease.
The parenteral route o' adinistration o' peptides accounted 'or the lar+est share o' around (2*
in ,ear 2011- in ters o' routes o' adinistration3 however other routes o' adinistration like
oral- pulonar,- nasal and intraderal are also bein+ tested and are estiated to e/perience
health, +rowth rate durin+ the 'orecast period.
Technolo+ical enhanceent with introduction o' h,brid technolo+, alon+ with solid phase peptide
s,ntheses 4SPPS5 is e/pected to enhance the +rowth o' peptide therapeutics. The h,brid
technolo+, se+ent which provides the best o' both solid and li6uid s,ntheses is now bein+
adopted b, a7or pla,ers and hence this arket is e/pected to see the hi+hest +rowth o' 12.1*
'ro 2012 to 201(.
Transparenc% Market Research
2
R/P0R1 D/SCR2P120'
Market
The 8orth $erican peptide therapeutics arket held a7orit, o' the arket share o'
appro/iatel, 40* in 2011 owin+ to its developed econo,. 9owever- due to rise in cost
containent and bud+etar, cuts in 8orth $erica- eer+in+ countries such as :ndia- #hina and
other ;atin $erican countries is e/pected to see a health, +rowth in the stud, period.
Soe o' the ke, arket pla,ers are <li ;ill,- &oche- $,lin- 8ovo=8ordisk- :psen and others. The
contract anu'acturin+ or+ani0ation 4#M>5 industr, includes a7or pla,ers such as ?ache-
Pol,peptide %roup- ;on0a- Peptis,ntha and others.
Peptide Therapeutics Market- b, $pplications
#ancer
Metabolic
#ardiovascular
Deratolo+,
$nti=:n'ection
8eurolo+,
%astro :ntestinal
&enal
&espirator,
Pain
>thers
Peptide Therapeutics Market- b, &oute o' $dinistration
Parenteral
>ral
Pulonar,
3
Market
Mucosal
>thers
Peptide Therapeutics Market- b, T,pes
:nnovative
%enerics
Peptide Therapeutics Market- b, $P: Peptide
:n=9ouse
#M> 4#ontract Manu'acturin+ >r+ani0ation5
Peptide Therapeutics b, technolo+,
;i6uid Phase Peptide S,nthesis 4;PPS5
Solid Phase Peptide S,nthesis 4SPPS5
9,brid
Peptide Therapeutics Market- b, %eo+raph,
8orth $erica
<urope
$sia
&o@
3or Sa*ple Report 4isit 0n:
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=!"
4
Market
C!apter 1 2ntro"uction
1-1 Report "escription
1-2 Mar.et seg*entation
1-# Scope o+ t!e report
1-4 Researc! *et!o"olog&
1-5 5ssu*ptions
C!apter 2 /6ecuti7e Su**ar&
2-1 8loal pepti"e t!erapeutics *ar.et re7enues9 2010 : 2018 ;USD Million<
2-1-1 8loal pepti"e t!erapeutics *ar.et re7enues9 & region9 2010 $ 2018 ;USD Million<
2-1-2 8loal 5P2 pepti"e t!erapeutics *ar.et9 2011 ;USD Million<
2-1-# 8loal pepti"e t!erapeutics *ar.et9 & route o+ a"*inistration9 2011 = 2018 ;><
C!apter # 8loal Pepti"e 1!erapeutics Mar.et D&na*ics
#-1 07er7ie(
#-2 Dri7ers
#-2-1 2ncrease in cancer patient population to propel t!e gro(t! o+ ne( pepti"es
!
15%L/ 03 C0'1/'1
Market
#-2-2 Rise in *etaolic "isor"ers to escalate t!e gro(t! o+ pepti"es *ar.et
#-2-# Rise in R=D pipeline o+ pepti"e "rugs is e6pecte" to ring consi"erale gro(t! in
co*ing &ears
#-2-#-1 8loal pepti"e t!erapeutics trials gro(t!9 1970 $ 2011
#-2-4 1ec!nological en!ance*ent !as ooste" t!e gro(t! o+ t!e *ar.et (it! ra"ical
re"uction in total pro"uction cost o+ pepti"es
#-# Restraints = c!allenges
#-#-1 2ncreasing co*ple6it& o+ pepti"es is a !uge c!allenge +or *anu+acturers
#-#-2 Lac. o+ regulator& stan"ar"s !a*pering t!e gro(t! o+ t!e *ar.et
#-#-# Matc!ing e)uip*ents (it! custo*er re)uire*ents is a *a?or c!allenge +or 5P2
pepti"e *anu+acturers
#-4 0pportunities
#-4-1 Rise in cancer 7accine to "ri7e t!e +uture *ar.et
#-4-2 8eneric pepti"es *ar.et to @ouris! (it! patent cliA e6pecte" in t!e +orecast perio"
#-4-# S*all iotec! Br*s collaorating (it! large p!ar*aceutical co*panies to e6plore
+urt!er gro(t!
#-4-#-1 8loal scenario o+ ac)uisitions o+ iotec! Br*s & large p!ar*a giants
#-4-#-2 Ma?or pepti"e "rugs an" sales9 2011 ;USD Million<
#-5 Porters B7e +orces anal&sis
#-5-1 PorterCs B7e +orces anal&sis o+ gloal pepti"e t!erapeutics *ar.et
#-5-2 %argaining po(er o+ suppliers
2
Market
#-5-# %argaining po(er o+ u&ers
#-5-4 1!reat o+ ne( entrants
#-5-5 1!reat o+ sustitutes
#-5-D Co*petiti7e ri7alr&
#-D Mar.et attracti7eness anal&sis
#-D-1 Mar.et attracti7eness anal&sis o+ t!e pepti"e t!erapeutics *ar.et & geograp!&
#-7 Pepti"e t!erapeutics $ e*erging tec!nologies = tren"s
#-8 Regulator& policies
C!apter 4 8loal Pepti"e 1!erapeutics Mar.et 5nal&sis9 %& 5pplications
4-1 2ntro"uction
4-1-1 8loal pepti"e t!erapeutics *ar.et re7enue9 & applications 2012$2018 ;USD Million<
4-1-2 Cancer
4-1-2-1 8loal cancer pepti"e t!erapeutics pipeline "rugs anal&sis9 nu*er o+ trials9
2009 $ 2012
4-1-2-2 8loal cancer pepti"e t!erapeutics *ar.et re7enues9 2010 : 2018 ;USD
Million<
4-1-# Metaolic
4-1-#-1 8loal *etaolic pepti"e t!erapeutics pipeline "rugs anal&sis9 nu*er o+
trials9 2009 $ 2012
)
Market
4-1-#-2 8loal *etaolic pepti"e t!erapeutics *ar.et re7enues9 2010 : 2018 ;USD
Million<
4-1-4 Car"io7ascular
4-1-4-1 8loal car"io7ascular pepti"e t!erapeutics pipeline "rugs anal&sis9 nu*er o+
trials9 2009 $ 2012
4-1-4-2 8loal car"io7ascular pepti"e t!erapeutics *ar.et re7enues9 2010 : 2018
;USD Million<
4-1-5 Der*atolog&
4-1-5-1 8loal "er*atolog& pipeline "rugs anal&sis9 nu*er o+ trials9 2009 $ 2012
4-1-5-2 8loal "er*atolog& pepti"es *ar.et re7enues9 2010 : 2018 ;USD Million<
4-1-D 5nti$2n+ection
4-1-D-1 8loal anti$in+ection "rugs anal&sis9 nu*er o+ trials9 2009 $ 2012
4-1-D-2 8loal anti$in+ection pepti"es *ar.et re7enues9 2010 : 2018 ;USD Million<
4-1-7 'eurolog&
4-1-7-1 8loal neurolog& pipeline "rugs anal&sis9 nu*er o+ trials9 2009 $ 2012
4-1-7-2 8loal neurolog& pepti"es *ar.et re7enues9 2010 : 2018 ;USD Million<
4-1-8 8astro 2ntestinal
4-1-8-1 8loal gastro intestinal pipeline "rugs anal&sis9 nu*er o+ trials9 2009 $ 2012
4-1-8-2 8loal gastro intestinal pepti"es *ar.et re7enues9 2010 $ 2018 ;USD Million<
4-1-9 Renal
4-1-9-1 8loal renal pipeline "rugs anal&sis9 nu*er o+ trials9 2009 $ 2012
(
Market
4-1-9-2 8loal renal pepti"es *ar.et re7enues9 2010 : 2018 ;USD Million<
4-1-10 Respirator&
4-1-10-1 8loal respirator& pipeline "rugs anal&sis9 nu*er o+ trials9 2009 $ 2012
4-1-10-2 8loal respirator& pepti"es *ar.et re7enues9 2010 : 2018 ;USD Million<
4-1-11 Pain
4-1-11-1 8loal pain pipeline "rugs anal&sis9 nu*er o+ trials9 2009 $ 2012
4-1-11-2 8loal pain pepti"es *ar.et re7enues9 2010 $ 2018 ;USD Million<
4-1-12 0t!ers
4-1-12-1 8loal ot!er pipeline "rugs anal&sis9 nu*er o+ trials9 2009 $ 2012
4-1-12-2 8loal ot!er pepti"es *ar.et re7enues9 2010 : 2018 ;USD Million<
C!apter 5 8loal Pepti"e 1!erapeutics Mar.et9 & Route o+ 5"*inistration
5-1 2ntro"uction
5-1-1 8loal pepti"e t!erapeutics *ar.et re7enues9 & route o+ a"*inistration9 2010 $ 2018
;USD Million<
5-1-2 Met!o"s o+ "eli7er& +or pepti"e "rugs
5-2 Parenteral Route
5-2-1 8loal pepti"e t!erapeutics *ar.et re7enues9 & parenteral route o+ a"*inistration9
2010 $ 2018 ;USD Million<
5-# 0ral Route
"
Market
5-#-1 8loal pepti"e t!erapeutics *ar.et re7enues9 & oral route o+ a"*inistration9 2010 $
2018 ;USD Million<
5-4 Pul*onar& Route
5-4-1 8loal pepti"e t!erapeutics *ar.et re7enues9 & pul*onar& route o+ a"*inistration9
5-5 Mucosal Route
5-5-1 8loal pepti"e t!erapeutics *ar.et re7enues9 & *ucosal route o+ a"*inistration9
5-D 0t!ers ;2ntra"er*al = 'asal<
5-D-1 8loal pepti"e t!erapeutics *ar.et re7enues9 & ot!er routes o+ a"*inistration9
C!apter D Pepti"e 1!erapeutics Mar.et : 8eneric = 2nno7ati7e Seg*ents
D-1 2ntro"uction
D-1-1 8loal pepti"e t!erapeutics *ar.et9 & t&pes re7enues9 2010 $ 2018 ;USD *illion<
D-2 Pepti"e 1!erapeutics : 2nno7ati7e *ar.et
D-2-1 8loal inno7ati7e pepti"e t!erapeutics *ar.et re7enues9 2010 $ 2018 ;USD Million<
D-# Pepti"e 1!erapeutics : 8eneric *ar.et
D-#-1 8loal generic pepti"e t!erapeutics *ar.et re7enues9 2010 $ 2018 ;USD Million<
C!apter 7 5P2 Pepti"e 1!erapeutics Mar.et9 2n$!ouse 4s CM0
10
Market
7-1 2ntro"uction
7-2 5P2 pepti"e t!erapeutics : 2n$!ouse *ar.et
7-2-1 8loal 5P2 pepti"e t!erapeutics in$!ouse *ar.et re7enues9 2010$2018 ;USD Million<
7-# Contract Manu+acturing 0rganiEations ;CM0<
7-#-1 8loal 5P2 pepti"e t!erapeutics CM0s *ar.et re7enues9 2010 $ 2018 ;USD Million<
C!apter 8 Pepti"e 1!erapeutics Mar.et9 %& 1ec!nolog&
8-1 2ntro"uction
8-1-1 8loal pepti"e t!erapeutics *ar.et re7enues9 & tec!nolog&9 2010 : 2018 ;USD
Million<
8-2 Soli" P!ase Pepti"e S&nt!esis ;SPPS<
8-2-1 8loal pepti"e t!erapeutics SPPS tec!nolog& *ar.et re7enues9 2010 $ 2018 ;USD
Million<
8-# Li)ui" P!ase Pepti"e S&nt!esis ;LPPS<
8-#-1 8loal pepti"e t!erapeutics LPPS tec!nolog& *ar.et re7enues9 2010 $ 2018 ;USD
Million<
8-4 F&ri" 1ec!nolog&
8-4-1 8loal pepti"e t!erapeutics !&ri" tec!nolog& *ar.et re7enues9 2010 $ 2018 ;USD
Million<
C!apter 9 Pepti"e 1!erapeutics Mar.et9 %& 8eograp!&
11
Market
9-1 2ntro"uction
9-1-1 8loal pepti"e t!erapeutics *ar.et s!are9 & geograp!&9 2011 $ 2018
9-2 'ort! 5*erica
9-2-1 'ort! 5*erica pepti"e t!erapeutics *ar.et re7enues9 2010 : 2018 ;USD Million<
9-# /urope
9-#-1 /urope pepti"e t!erapeutics *ar.et re7enues9 2010 : 2018 ;USD Million<
9-4 5sia
9-4-1 5sia pepti"e t!erapeutics *ar.et re7enues9 2010 $ 2018 ;USD Million<
9-5 Rest o+ Gorl"
9-5-1 RoG pepti"e t!erapeutics *ar.et re7enues9 2010 $ 2018 ;USD Million<
C!apter 10 Mar.et S!are 5nal&sis
10-1 Mar.et s!are & .e& pla&ers
10-2 Mar.et s!are & .e& pla&ers in pepti"e "rugs *ar.et
10-2-1 8loal pepti"e t!erapeutics *ar.et s!are anal&sis o+ .e& pla&ers9 2011 ;><
10-# Mar.et s!are & .e& pla&ers in CM0 seg*ent
10-#-1 8loal pepti"e t!erapeutics: *ar.et s!are anal&sis o+ .e& CM0 pla&ers9 2011 ;><
C!apter 11 Reco**en"ations
11-1 Success strategies
12
Market
11-1-1 Rigorous researc! an" "e7elop*ent ;R=D< initiati7es
11-1-2 2n7esting in e*erging econo*ies
11-1-# 2n7esting in recent tec!nologies suc! as FPPS 1/c!nolog&
11-1-4 Mergers an" ac)uisitions
11-2 %arriers to e consi"ere"
11-2-1 1!e !ig! cost o+ pepti"e s&nt!esis
11-2-2 Gea. pipeline pepti"e "rug can"i"ates in p!ase 222
C!apter 12 Co*pan& ProBles
12-1 %ac!e* Fol"ing 58
12-1-1 Co*pan& o7er7ie(
12-1-2 3inancial o7er7ie(
12-1-# Strategic o7er7ie(
12-1-#-1 Collaorations
12-1-#-2 /6pansion
12-1-#-# Di7estiture
12-1-#-4 Recent "e7elop*ents
12-2 /li Lill& an" Co*pan&
13
Market
12-2-#-1 5gree*ents
12-2-#-2 5ppro7als
12-2-4 Recent "e7elop*ents
12-# PBEer9 2nc-
12-#-1 Co*pan& o7er7ie(
12-#-2 3inancial o7er7ie(
12-#-# Strategic o7er7ie(
12-#-#-1 Mergers an" ac)uisitions
12-#-#-2 Di7estiture
12-#-#-# 5ppro7als
12-#-4 Recent "e7elop*ents
12-4 5*gen9 2nc-
12-4-#-1 Mergers an" ac)uisitions
12-4-#-2 Licensing
12-5 1a.e"a P!ar*aceutical Co*pan& Li*ite"
14
Market
12-5-#-1 Partners!ips an" collaorations
12-D 1e7a P!ar*aceuticals
12-D-1 Co*pan& o7er7ie(
12-D-2 3inancial o7er7ie(
12-D-# Strategic o7er7ie(
12-D-#-1 Mergers an" ac)uisitions
12-D-#-2 2n7esting in generic an" iosi*ilar seg*ents
12-D-4 Recent "e7elop*ents
12-7 LonEa 2nc-
12-7-#-1 2n7esting in e*erging econo*ies
1!
Market
12-8 Peptis&nt!a
12-8-#-1 5rranging an" participating in tra"e s!o(s
12-8-#-2 Continuous *anu+acturing e6pansion
12-9 SanoB
12-9-#-1 5c)uisitions
12-9-#-2 Di7est*ents
12-10 2psen
12-10-#-1 Large in7est*ent in researc! an" "e7elop*ent
12-10-#-2 8loal e6pansion t!roug! partners!ip
12
Market
12-11 Pol&Pepti"e 8roup-
12-11-2 Strategic o7er7ie(
12-11-2-1 3ocus on pro"uct port+olio e6tension an" )ualit& pro"uct "e7elop*ent
12-11-2-2 8loal e6pansion t!roug! *erger an" ac)uisition
12-12 5*&lin P!ar*aceuticals LLC $ %ristol$M&ers S)ui ;%MS<
12-12-2 5*&lin P!ar*aceuticals LLC
12-12-# 3inancial o7er7ie(
12-12-4 Strategic o7er7ie( ;5*&lin P!ar*aceuticals LLC<
12-12-4-1 /ntering into strategic collaorations
12-12-4-2 Corporate social responsiilit&
12-12-4-# Rigorous R=D initiati7es
12-1# 5straHeneca PLC
12-1#-1 Co*pan& o7er7ie(
12-1#-2 3inancial o7er7ie(
12-1#-# Strategic o7er7ie(
12-1#-#-1 Rigorous R=D initiati7es
12-1#-#-2 2n7esting in e*erging econo*ies
1)
Market
12-1#-4 Recent "e7elop*ents
12-14 Roc!e
12-14-#-1 Researc! an" "e7elop*ent initiati7es
12-14-#-2 3ocus on personaliEe" !ealt!care
12-14-#-# 3ocus on ne( an" e*erging *ar.ets
12-14-#-4 3un"ing a(areness progra*s
12-15 8la6oS*it!Iline ;8SI<
12-15-#-1 Researc! an" "e7elop*ent initiati7es
12-15-#-2 Direct to Consu*er 5"7ertising
12-15-#-# Mergers an" ac)uisitions
12-1D Merc. = Co-
12-1D-1 Co*pan& o7er7ie(
1(
Market
12-1D-2 3inancial o7er7ie(
12-1D-# Strategic o7er7ie(
12-1D-#-1 Corporate social responsiilit&
12-1D-#-2 R=D 2nitiati7es
12-1D-#-# Strategic alliances an" out$licensing
12-1D-4 Recent "e7elop*ents
12-17 'o7artis 58
12-17-#-2 Me*oran"u* o+ un"erstan"ing
12-18 'o7o$'or"is. 5,S
12-18-#-1 Partners!ips an" alliances
12-18-4 5gree*ents
1"
Market
Transparenc, Market &esearch is a arket intelli+ence copan, providin+ +lobal business in'oration
reports and services. >ur e/clusive blend o' 6uantitative 'orecastin+ and trends anal,sis provides 'orward=
lookin+ insi+ht 'or thousands o' decision akers.
@e are privile+ed with hi+hl, e/perienced tea o' $nal,sts- &esearchers and #onsultants- who use
proprietar, data sources and various tools and techni6ues to +ather- and anal,0e in'oration. >ur
business o.erin+s represent the latest and the ost reliable in'oration indispensable 'or businesses to
sustain a copetitive ed+e.
Contact:
Transparenc, Market &esearch
"0 State Street-
Suite )00-
$lban,
8A = 1220)
United States
TelB C1=!1(=21(=1030
US$ = #anada Toll Dree (22=!!2=34!3
<ailB salesEtransparenc,arketresearch.co
@ebsiteB httpBFFwww.transparenc,arketresearch.coF
20
5out Us

Transparency Market Research

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Transparency Market Research

Uploaded by

Copyright:

Available Formats

Transparency Market

You might also like